Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.44 |
| ▸ | LPL | P06858 | 7/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6312527 | 0.80 | LIPG (0.42) | LIPGLPLHIF1AROCK1 | |
| SCHEMBL15639230 | 0.79 | CA1 (0.41) | LIPGLPLHIF1ACA1CA2 | |
| SCHEMBL5761327 | 0.77 | MEN1 (0.54) | LIPGLPLHIF1ACA1CA2 | |
| SCHEMBL15638728 | 0.76 | LIPG (0.36) | LIPGLPLHIF1ACA1CA2 | |
| SCHEMBL17315510 | 0.76 | HIF1A (0.46) | LIPGLPLHIF1ACA1CA2 | |
| SCHEMBL15376138 | 0.75 | LIPG (0.46) | LIPGLPLHIF1ACA1CA2 | |
| SCHEMBL25330897 | 0.75 | LIPG (0.44) | LIPGLPLHIF1ACA1CA2 | |
| SCHEMBL22264962 | 0.75 | CYP1A2 (0.44) | LIPGLPLPPARGPPARAHIF1A | |
| SCHEMBL22264963 | 0.75 | CYP1A2 (0.44) | LIPGLPLPPARGPPARAHIF1A | |
| SCHEMBL25330900 | 0.75 | LIPG (0.44) | LIPGLPLHIF1ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988484-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORP LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-10273248-B2 | Glucose uptake inhibitors | Kadmon Corportion, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180298029-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION LLC (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3313825-A1 | GLUCOSE UPTAKE INHIBITORS | Kadmon Corporation, LLC (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210330-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298029-A1 | GLUCOSE UPTAKE INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | LIPG 917/4885LPL 1602/4885PPARG 292/4885 |
| US-10988484-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A2, SLC2A4 | LIPG 947/4885LPL 1503/4885PPARG 301/4885 |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | SLC2A1, SLC2A4, SLC2A2 | LIPG 1488/4885LPL 2519/4885PPARG 522/4885 |
| US-10273248-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A2, SLC2A4 | LIPG 917/4885LPL 1602/4885PPARG 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.